WordNet

suffering from dyspepsia
a person suffering from indigestion
a disorder of digestive function characterized by discomfort or heartburn or nausea (同)dyspepsia, stomach upset, upset stomach

PrepTutorEJDIC

消化不良の / 憂うつな / 消化不良の人,胃腸障害の人
消化不良,不消化
消化不良,胃腸障害

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/12/23 13:58:57」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 消化不良成人患者へのアプローチ approach to the adult with dyspepsia
2. 成人における機能性胃腸症 functional dyspepsia in adults
3. Functional abdominal pain in children and adolescents: Management in primary care
4. 悪心および嘔吐を呈する幼児または小児に対するアプローチ approach to the infant or child with nausea and vomiting
5. 消化性潰瘍：臨床症状および診断 peptic ulcer disease clinical manifestations and diagnosis

English Journal

Comparison of Encapsulated Versus Nonencapsulated (14) C-urea Breath Test for the Detection of Helicobacter pylori Infection: A Scintigraphy Study.

Pathak CM1, Kaur B, Bhasin DK, Mittal BR, Sharma S, Khanduja KL, Aggarwal L, Rana SS.Author information 1Department of Biophysics, Post Graduate Institute of Medical Education and Research, Chandigarh, India.AbstractBACKGROUND AND AIMS: (14) C-urea breath test ((14) C-UBT) is considered as "gold standard" for detection of active gastric H. pylori infection. However, till date no comparative study using encapsulated and non-encapsulated (14) C-UBT protocols has been conducted in same subjects in identical conditions. We monitored gastric fate of capsule containing (14) C-urea with real time display and compared sensitivities of these protocols at different time points of breath collection.
Helicobacter.Helicobacter.2014 Apr;19(2):116-23. doi: 10.1111/hel.12103. Epub 2013 Nov 18.
BACKGROUND AND AIMS: (14) C-urea breath test ((14) C-UBT) is considered as "gold standard" for detection of active gastric H. pylori infection. However, till date no comparative study using encapsulated and non-encapsulated (14) C-UBT protocols has been conducted in same subjects in identical condi
PMID 24237714

Efficacy and Safety of Cinitapride in the Treatment of Mild to Moderate Postprandial Distress Syndrome-predominant Functional Dyspepsia.

Du Y1, Su T, Song X, Gao J, Zou D, Zuo C, Xie W, Wang B, Zhang Z, Xu J, Tian D, Luo H, Zhang Z, Wang S, Chen J, Guo J, Gong L, Ding Y, Li Z.Author information 1Departments of *Gastroenterology †Nuclear Medicine, Shanghai Changhai Hospital, Second Military Medical University ‡Department of Gastroenterology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai §Department of Gastroenterology, Tianjin Medical University General Hospital ∥Department of Gastroenterology, The 2nd Hospital of Tianjin Medical University, Tianjin ¶Department of Gastroenterology, The First Affiliated Hospital of Anhui Medical University, Hefei #Department of Gastroenterology, Tongji Hospital, Huazhong University of Science & Technology **Department of Gastroenterology, People's Hospital of Wuhan University, Wuhan ††Department of Gastroenterology, Nanjing First Hospital, Nanjing ‡‡Department of Gastroenterology, The 2nd Affiliated Hospital of Soochow University, Suzhou §§Department of Gastroenterology, The 3rd Affiliated Hospital of Soochow University, Changzhou ∥∥Department of Gastroenterology, Wuxi People's Hospital ¶¶Department of Gastroenterology, Wuxi 2nd People's Hospital, Wuxi ##Department of Gastroenterology, Yangzhou 1st People's Hospital, Yangzhou, China.AbstractGOALS AND BACKGROUND: Functional dyspepsia (FD) is a complex disease with a variety of dyspeptic symptoms. Little is known about the clinical efficacy of cinitapride, a 5-HT4 agonist and D2 antagonist, in treating FD.
Journal of clinical gastroenterology.J Clin Gastroenterol.2014 Apr;48(4):328-35. doi: 10.1097/MCG.0000000000000033.
GOALS AND BACKGROUND: Functional dyspepsia (FD) is a complex disease with a variety of dyspeptic symptoms. Little is known about the clinical efficacy of cinitapride, a 5-HT4 agonist and D2 antagonist, in treating FD.STUDY: This randomized, double-blind, double-dummy, positive-controlled study compa
PMID 24440931

Randomised clinical trial: relief of upper gastrointestinal symptoms by an acid pocket-targeting alginate-antacid (Gaviscon Double Action) - a double-blind, placebo-controlled, pilot study in gastro-oesophageal reflux disease.

Thomas E1, Wade A, Crawford G, Jenner B, Levinson N, Wilkinson J.Author information 1Category Development Organisation, Reckitt Benckiser, Slough, UK.AbstractBACKGROUND: The alginate-antacid, Gaviscon Double Action (Gaviscon DA; Reckitt Benckiser, Slough, UK) suppresses reflux after meals by creating a gel-like barrier that caps and displaces the acid pocket distal to the oesophago-gastric junction. The effect of Gaviscon DA on reflux and dyspepsia symptoms has not yet been demonstrated with a modern trial design.
Alimentary pharmacology & therapeutics.Aliment Pharmacol Ther.2014 Mar;39(6):595-602. doi: 10.1111/apt.12640. Epub 2014 Jan 28.
BACKGROUND: The alginate-antacid, Gaviscon Double Action (Gaviscon DA; Reckitt Benckiser, Slough, UK) suppresses reflux after meals by creating a gel-like barrier that caps and displaces the acid pocket distal to the oesophago-gastric junction. The effect of Gaviscon DA on reflux and dyspepsia sympt
PMID 24471505

Efficacy of Helicobacter pylori Eradication Therapy on Functional Dyspepsia: A Meta-Analysis of Randomized Controlled Studies With 12-Month Follow-up.

Zhao B1, Zhao J, Cheng WF, Shi WJ, Liu W, Pan XL, Zhang GX.Author information 1*Department of Gastroenterology, Shengze Hospital of Nanjing Medical University, Wujiang, Jiangsu †Department of Gastroenterology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China.AbstractBACKGROUND: Whether patients with functional dyspepsia (FD) should receive Helicobacter pylori eradication therapy remains controversial.
Journal of clinical gastroenterology.J Clin Gastroenterol.2014 Mar;48(3):241-7. doi: 10.1097/MCG.0b013e31829f2e25.
BACKGROUND: Whether patients with functional dyspepsia (FD) should receive Helicobacter pylori eradication therapy remains controversial.AIMS: This meta-analysis was to evaluate the long-term effects of H. pylori eradication on dyspeptic symptoms of patients with FD, by selecting the most recent wel
PMID 24002127

Japanese Journal

3. 術後の食欲不振と六君子湯(<特集>外科医のためのKampo EBM UP TO DATE)

矢内充洋,持木彫人,桑野博行
日本外科学会雑誌 114(5), 236-240, 2013-09-01
NAID 110009657873

Gastric hypochlorhydria is associated with an exacerbation of dyspeptic symptoms in female patients

IWAI Wataru,ABE Yasuhiko,IIJIMA Katsunori,KOIKE Tomoyuki,UNO Kaname,ASANO Naoki,IMATANI Akira,SHIMOSEGAWA Tooru
Journal of gastroenterology 48(2), 214-221, 2013-02-01
NAID 10031156307

Interdigestive migrating motor complex -its mechanism and clinical importance

Takahashi Toku
Journal of Smooth Muscle Research 49(0), 99-111, 2013
… The impaired gastric MMC may aggravate dyspeptic symptoms following a food ingestion. … Maintaining MMC cycle in the interdigestive state is an important factor to prevent the postprandial dyspeptic symptoms. …
NAID 130003391241

Clinical Classification of Subgroups According to the Rome III Criteria Cannot be Used to Distinguish the Associated Respective Pathophysiology in Japanese Patients with Functional Dyspepsia

Ochi Masahiro,Tominaga Kazunari,Tanaka Fumio,Tanigawa Tetsuya,Yamagami Hirokazu,Watanabe Kenji,Watanabe Toshio,Fujiwara Yasuhiro,Arakawa Tetsuo
Internal Medicine 52(12), 1289-1293, 2013
… Objective Patients who meet the Rome III criteria for functional dyspepsia (FD) are generally classified into the following two subgroups, those with postprandial distress syndrome (PDS) and those with epigastric pain syndrome (EPS), in order to treat the dyspeptic symptoms caused by the respective pathophysiological conditions. …
NAID 130003365673